# Ultravist: Safety and Efficacy in Computed Tomography of Head and Body

> **NCT00244140** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 435 (actual)

## Conditions studied

- Computed Tomography
- Diagnostic Imaging

## Interventions

- **DRUG:** Iopromide 370 mg I/mL
- **DRUG:** Iopromide 300 mg I/mL

## Key facts

- **NCT ID:** NCT00244140
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 435 (ACTUAL)
- **Last updated:** 2014-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00244140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00244140, "Ultravist: Safety and Efficacy in Computed Tomography of Head and Body". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00244140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*